Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.42 per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $24.30 on Monday. The stock’s 50 day moving average price is $23.83 and its 200 day moving average price is $22.08. The firm has a market cap of $2.99 billion, a P/E ratio of 14.13, a PEG ratio of 0.81 and a beta of 0.74. Catalyst Pharmaceuticals has a 1 year low of $19.05 and a 1 year high of $26.58.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 10,983 shares of the company’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $23.33, for a total transaction of $256,233.39. Following the completion of the sale, the insider directly owned 3,962 shares in the company, valued at $92,433.46. This represents a 73.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Molly Harper sold 26,746 shares of Catalyst Pharmaceuticals stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total value of $621,844.50. Following the completion of the transaction, the director directly owned 2,360 shares in the company, valued at $54,870. This represents a 91.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 10.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CPRX. Advisory Services Network LLC purchased a new stake in Catalyst Pharmaceuticals during the third quarter worth approximately $39,000. Quarry LP purchased a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth $40,000. Smartleaf Asset Management LLC increased its holdings in Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 630 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Catalyst Pharmaceuticals by 17.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 469 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in Catalyst Pharmaceuticals in the fourth quarter valued at about $93,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Wall Street Zen raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a report on Friday, November 7th. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Monday, December 29th. Finally, Oppenheimer reissued an “outperform” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $33.20.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).